Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8476 to 8490 of 8990 results

  1. Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]

    Discontinued Reference number: GID-TA11569

    Technology appraisal guidance
    Discontinued

  2. Tiragolumab in combination for untreated advanced non-squamous non-small-cell lung cancer [ID6443]

    Discontinued Reference number: GID-TA11467

    Technology appraisal guidance
    Discontinued

  3. Ceralasertib with durvalumab for treating advanced non-small-cell lung cancer after antiPD-L1 treatment and platinum-based chemotherapy [ID6612]

    In development Reference number: GID-TA11800 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Tiragolumab with atezolizumab and bevacizumab for untreated unresectable or advanced hepatocellular carcinoma [TSID12238]

    In development Reference number: GID-TA11831 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Osimertinib for neoadjuvant treatment of EGFR mutation-positive resectable non-small-cell lung cancer [ID6472]

    In development Reference number: GID-TA11589 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Niraparib with pembrolizumab for maintenance treatment of advanced non-small-cell lung cancer after platinum-based chemotherapy with pembrolizumab [ID6345]

    In development Reference number: GID-TA11406 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6398]

    In development Reference number: GID-TA11500 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]

    In development Reference number: GID-TAG388 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]

    Discontinued Reference number: GID-TA11228

    Technology appraisal guidance
    Discontinued

  10. Favezelimab–pembrolizumab for previously treated PD-L1-positive metastatic colorectal cancer [ID6278]

    Discontinued Reference number: GID-TA11343

    Technology appraisal guidance
    Discontinued

  11. Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for early triple negative breast cancer [ID6200]

    Discontinued Reference number: GID-TA11165

    Technology appraisal guidance
    Discontinued

  12. Atezolizumab with chemotherapy for treating relapsing recurrent advanced triple-negative early breast cancer [ID6152]

    Discontinued Reference number: GID-TA11089

    Technology appraisal guidance
    Discontinued

  13. Xevinapant with platinum-based chemotherapy and radiotherapy for untreated locally advanced squamous cell head and neck cancer [ID6199]

    Discontinued Reference number: GID-TA11166

    Technology appraisal guidance
    Discontinued

  14. Colon cancer (adjuvant) - irinotecan [ID379]

    Discontinued Reference number: GID-TAG380

    Technology appraisal guidance
    Discontinued

  15. Atezolizumab with BCG before surgery (neoadjuvant) for treating non-muscle-invasive bladder cancer [ID6667]

    In development Reference number: GID-TA11884 Expected publication date: TBC

    Technology appraisal guidance
    In development